tetano
Editor, Senior Moderator
Acta Neurol Belg
. 2022 May 2.
doi: 10.1007/s13760-022-01941-0. Online ahead of print.
Neuromuscular complications after COVID-19 vaccination: a series of eight patients
Wouter Leemans[SUP] #[/SUP][SUP] 1 [/SUP], Sofie Antonis[SUP] #[/SUP][SUP] 2 [/SUP], Wouter De Vooght[SUP] 2 [/SUP], Robin Lemmens[SUP] 1 3 4 [/SUP], Philip Van Damme[SUP] 5 6 7 [/SUP]
Affiliations
Abstract
Background: Several neurologic complications have been reported in close temporal association with both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and following vaccination against SARS-CoV-2. Specifically, several cases of Guillain-Barré syndrome (GBS) have been reported in temporal relationship with COVID-19 vaccination, with two small case series describing a specific phenotype with bifacial weakness and paresthesia in the limbs.
Methods: We retrospectively collected patients who developed a new-onset neuromuscular disorder in the first 6 weeks after receiving a COVID-19 vaccine (either first or second dose). The patients were collected from one tertiary care centre and one secondary care centre from February to July 2021.
Results: We report eight patients who developed phenotypically diverse neuromuscular disorders in the weeks following COVID-19 vaccination, with a presumed immune-mediated etiology. In our case series, we report three patients with classical GBS, one patient with bifacial weakness with paresthesia variant of GBS, two patients with subacute-onset chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with brachial plexopathy and one patient with subacute axonal sensorimotor polyneuropathy.
Conclusions: New-onset neuromuscular disorders with onset in the weeks after COVID-19 vaccination can include diverse phenotypes. A causal relationship between these disorders and the vaccine cannot be proven at present, and further epidemiological studies are needed to further investigate this association.
Keywords: CIDP; COVID-19; Guillain-Barré; Neuromuscular; Vaccine.
. 2022 May 2.
doi: 10.1007/s13760-022-01941-0. Online ahead of print.
Neuromuscular complications after COVID-19 vaccination: a series of eight patients
Wouter Leemans[SUP] #[/SUP][SUP] 1 [/SUP], Sofie Antonis[SUP] #[/SUP][SUP] 2 [/SUP], Wouter De Vooght[SUP] 2 [/SUP], Robin Lemmens[SUP] 1 3 4 [/SUP], Philip Van Damme[SUP] 5 6 7 [/SUP]
Affiliations
- PMID: 35499704
- DOI: 10.1007/s13760-022-01941-0
Abstract
Background: Several neurologic complications have been reported in close temporal association with both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and following vaccination against SARS-CoV-2. Specifically, several cases of Guillain-Barré syndrome (GBS) have been reported in temporal relationship with COVID-19 vaccination, with two small case series describing a specific phenotype with bifacial weakness and paresthesia in the limbs.
Methods: We retrospectively collected patients who developed a new-onset neuromuscular disorder in the first 6 weeks after receiving a COVID-19 vaccine (either first or second dose). The patients were collected from one tertiary care centre and one secondary care centre from February to July 2021.
Results: We report eight patients who developed phenotypically diverse neuromuscular disorders in the weeks following COVID-19 vaccination, with a presumed immune-mediated etiology. In our case series, we report three patients with classical GBS, one patient with bifacial weakness with paresthesia variant of GBS, two patients with subacute-onset chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with brachial plexopathy and one patient with subacute axonal sensorimotor polyneuropathy.
Conclusions: New-onset neuromuscular disorders with onset in the weeks after COVID-19 vaccination can include diverse phenotypes. A causal relationship between these disorders and the vaccine cannot be proven at present, and further epidemiological studies are needed to further investigate this association.
Keywords: CIDP; COVID-19; Guillain-Barré; Neuromuscular; Vaccine.